2 0 11 A N N U A L R E P O R T

Growing our network To expand access to personalized care

Ralph Aye, M.D. Thoracic/Esophageal Surgery

Amir Bastawrous, M.D. Colon/Rectal Surgery

J. David Beatty, M.D. Breast Surgery

Aliki Birkenbuel, MHSA Manager, Cancer Registry

Candy Bonham, CTR Cancer Registry/Cancer Program Coordinator

Mark Bonnema, M.Div. Spiritual Care

Christopher Cannon, M.D. Surgery

Patricia Dawson, M.D. Breast Surgery

Albert Einstein Jr., M.D. Executive Director, Swedish Cancer Institute

Daniel Flugstad, M.D. Surgery

Philip Gold, M.D. Medical Oncology

Patra Grevstad, R.N., M.N. Research

John Henson, M.D. Neuro-Oncology

Marc Horton, M.D. General Surgery

Gordon Irving, M.D. Medical Director, Pain Management Services

Sandra Johnson, LICSW Oncology Social Services

Mary Kelly, M.D. Diagnostic Radiology

Namou Kim, M.D. Head and Neck Surgery

Barbara Kollar, MHA, CHES Patient Education/Integrated Care

Dan Labriola, N.D. Naturopathic Medicine

Shannon Marsh American Cancer Society Patient Navigation Representative

Vivek Mehta, M.D. Radiation Oncology

Michael Milder, M.D. Medical Oncology/Internal Medicine

David Moore, M.D. Head and Neck Surgery

Jay Parikh, M.D. Diagnostic Radiology

James Porter, M.D. Urological Surgery

Robert Resta, M.S., CGC Hereditary Cancer Clinic

Carlotta Reynolds, R.N. Nurse Manager, Inpatient Oncology

2011 Cancer Committee Membership Roster Sara Rigel, MPH, CHES Manager, Patient/Family Education and Community Health

Eric Rosen, M.D. Diagnostic Radiology

Nancii Stonebraker, R.D., C.D. Manager, Clinical Nutrition

Alexis Takasumi, CHES Medical Education

Mariko Tameishi, MHA Informatics Specialist

Nancy Thompson, R.N., M.S., AOCNS Outpatient Clinical Nursing

Ronald Tickman, M.D.* Pathology

Lanny Turay, R.Ph. Clinical Pharmacy

Dan Veljovich, M.D. Gynecological Oncology

John Wynn, M.D. Psycho-Oncology

Jim Yates, MSPH, MBA Administrative Director Swedish Cancer Institute & First Hill Service Lines

Jon Younger, M.D. Internal Medicine/Hospice Director

David Zucker, M.D., Ph.D. Medical Director, Cancer Rehabilitation Services

*2010 Cancer Committee Chairman

Cover Photo: This photo represents just a few of the many individuals who work together as a close-knit team to provide the personalized cancer care that is the hallmark of the Swedish Cancer Institute (SCI). Standing (left to right): A.B. Einstein, M.D. (SCI executive director), Philip Gold, M.D. (medical oncology/research), Robert Resta, M.S., CGC (genetic counseling), Brian Louie, M.D. (thoracic/esophageal surgery), Daniel Labriola, N.D. (naturopathic medicine), Todd Barnett, M.D. (radiation oncology), Genevieve Vergara (clinical support), Linda Cole, R.N., BSN, OCN, (infusion therapy), Jim Yates, MSPH, MBA (SCI administration), Darren Ronald Pollock, M.D. (colon/rectal surgery), Michael Milder, M.D. (medical oncology), David Zucker, M.D., Ph.D. (physiatry/physical rehabilitation), Ronald Tickman, M.D. (pathology), Brian Higginson, R.D., C.D. (clinical nutrition); and seated (left to right) Sandra Johnson, MSW, LICSW (patient support services), Kelsey Jenison (patient education), Heidi Hohmann, BSN, OCN (nursing), Lanny Turay, R.Ph. (pharmacy), Dorcas Dobie, M.D. (psychiatry), Patricia Dawson, M.D., Ph.D. (breast cancer surgery).

The Swedish Cancer Institute: Growing our network To expand access to personalized care

For nearly eighty years the men and women of the Swedish Cancer Institute (SCI) have been relentless pioneers in developing and making available the latest cancer-fighting technologies and therapies. Their quest has been driven by one constant – a desire to create the most personalized treatment plans in order to produce the best possible outcomes for each of their cancer patients.

Looking forward The Swedish Cancer Institute has an eye on the current uncertainties of the changing health-care environment. It is squarely focused, however, on a future in which advancements in cancer prevention, diagnosis and treatment fuel increased demand for the comprehensive – and cost-effective – approach to cancer care that is available at the SCI.

The Swedish Cancer Institute – Vision 2020 The Swedish Cancer Institute will be recognized throughout the Northwest as the premier network of integrated centers in which multidisciplinary teams of highly skilled health-care professionals use the latest technologies to provide comprehensive, personalized and cost-effective care to produce exceptional outcomes.

TABLE OF CONTENTS

Letter from the Executive Director, 2 Swedish Cancer Institute

Letter from the Chairman, 3 SCI Cancer Committee

Gastrointestinal Cancer: 4 A cohesive, comprehensive approach to cancer care

Clinical Trials at the 11 Swedish Cancer Institute

SCI Open Research Studies 11

Swedish/Edmonds Expanding 14 to Improve Cancer Services

SCI at Issaquah Serving 17 the Eastside

Donations Expand the Reach 18 of SCI’s Cancer-Fighting Team

Swedish Cancer Registry 2010 19

SCI Bibliography 20

A Message from the Executive Director, Swedish Cancer Institute

Over the past 12 years, the Swedish Cancer Institute (SCI) has experienced dynamic evolution and growth, producing a regional network of cancer care providers that is second to none. In that decade, the SCI has become a truly comprehensive cancer treatment and research program committed to the personalized care of every patient at the highest level.

Patients in the Puget Sound area can be confident they are getting optimal cancer treatment close to home and easy access to exceptional expertise and technology when needed. We treat them as unique individuals, developing customized treatment plans and providing supportive care to facilitate their treatment and survivorship experience.

Our clinicians have the latest technology and newest drugs to optimize their patients’ outcomes. Our physicians are engaged in clinical research to evaluate new drugs and treatment approaches and report on the treatment experience at the SCI. Many physicians hold leadership positions in national and regional professional organizations and clinical research groups. The quality of our care and the safety of our patients are high priorities with our staff who continuously strive for improvement.

In 1999, Swedish invited me to return to Seattle to help develop this wonderful program. In January 2012, I will retire to spend more time with my family, boating and traveling. It has been my privilege and pleasure to have served as the executive director of the Swedish Cancer Institute during this period of extraordinary growth, and I am forever grateful for the opportunity to impact the care of so many patients.

Above all, it has been an honor to work with the wonderful SCI and Swedish staff – physicians, nurses, support staff, administrative staff, research staff, pharmacists, technical staff, medical physicists and others – all of whom are committed to our vision and mission. We have been able to recruit some of the best experts in their fields to join our already talented and committed staff. While contributing to the much needed clinical research effort and the education of all, we have always kept the focus of our energies on our primary mission – the optimal care of our patients.

Together, we have accomplished a lot, but there always will be more to do. Swedish’s potential affiliation with the Providence organization will certainly provide new opportunities for the SCI to grow and positively influence the care of cancer patients over a larger region. Future health-care reforms will surely change how care is provided and paid for. I am, however, confident Swedish will always hold the interests of our patients foremost as it adapts to these changes. I leave knowing the Swedish Cancer Institute is well-positioned to meet the challenges and opportunities ahead.

Albert B. Einstein Jr., M.D. Executive Director, Swedish Cancer Institute

2

Albert B. Einstein Jr., M.D.

A Message from the Chairman of the SCI Cancer Committee

During the last 18 months, the Swedish Cancer Institute’s Cancer Committee has focused on various projects to enhance the delivery of safe, high-quality cancer care throughout the SCI network. In addition to supporting the most visible initiatives – opening SCI at Swedish/Issaquah and beginning construction on the new SCI building at Swedish/Edmonds – the committee also has made great progress on a project that may have a lower profile, but is certain to have a positive effect on a broad population of patients.

With the leadership of the Cancer Registry subcommittee, the SCI is preparing to voluntarily participate in a pilot program of the Commission on Cancer (CoC) to improve data collection systems and processes in order to establish a nationwide system of rapid reporting/real-time response. Having this database available in real-time will ensure the personalized care we provide each of our patients also meets national staging and treatment guidelines that have been shown to provide the best outcomes.

We currently maintain data in each patient’s Swedish electronic medical record (EMR). This data includes patient demographics, cancer staging, tumor and histological characteristics, type and course of treatment, and outcomes information. Capturing and accurately transferring that data to

a national database, however, is both time and personnel intensive. By taking full advantage of electronic interfaces between the EMR, Cancer Registry and National Cancer Database (NCDB), we will be assuring accuracy of the data while improving efficiency and overall functionality. This type of real-time resource will benefit physicians and patients by providing that added confidence that they are on the best possible course of treatment.

J. David Beatty, M.D., is one of the long-time champions of this initiative and was recently recognized for his leadership, receiving the Commission on Cancer State Chair Outstanding Achievement Award. I extend my congratulations to Dr. Beatty on behalf of the Cancer Committee and the entire staff of the Swedish Cancer Institute. We are privileged to have many dedicated individuals like Dr. Beatty who are committed to continually evaluating and improving not only the way we diagnose and treat cancer, but also the way we document our efforts so our decisions and actions can be a benefit to others.

Ronald J. Tickman, M.D. Chairman, SCI Cancer Committee

Ronald J. Tickman, M.D.

3

Swedish Medical Center and the Swedish Cancer Institute (SCI) have long recognized the great burden gastrointestinal cancers place on patients, families and the health-care system. In response, the SCI has expanded its physician expertise, surgical and endoscopic capabilities, radiation therapy technologies, and state-of-the-art facilities to evolve from a Seattle-centric gastrointestinal cancer program into one of the most comprehensive cancer-care networks on the West Coast.

The SCI Gastrointestinal Program promotes:• Personalized care that focuses on improving both clinical outcomes

and quality of life• Clinical research that may offer new therapies and identify best practices• An educational program to share experience and expertise with medical

practitioners from around the world

“The SCI and our GI cancer team are committed to advancing the prevention, detection and treatment of GI cancer,” says Philip Gold, M.D., program leader of the GI Cancer Program and medical director of Clinical Research at the SCI. “It is the close collaboration we foster among specialists from multiple disciplines, along with the institutional investment in the most advanced technology that places SCI’s GI Cancer Program among the premier programs on the West Coast. Our patients choose Swedish because of our team approach and our ability to provide state-of-the-art diagnostics and the newest therapies – all under one roof and in a highly cohesive way.”

Philip Gold, M.D.

4

Gastrointestinal Cancer: A cohesive, comprehensive approach to cancer care

5

GI Tumor Board exemplifies teamwork

The foundation of the GI Cancer Program’s approach is the GI Tumor Board, which Dr. Gold implemented shortly after his arrival at Swedish over a decade ago. The GI Tumor Board puts the aspiration of collaboration into every-day practice. It is the forum for specialists from numerous disciplines to confer about treatment options for every type of GI cancer case – from the routine to those cases that are extremely challenging. The GI Tumor Board comprises a broad range of specialties, including medical and radiation oncology, pathology, radiology, gastroenterology, endoscopy, thoracic and hipatobiliary surgery, and surgical oncology. Each participant contributes experience, expertise and knowledge of the latest therapies, as well as information about relevant clinical research studies. Together they are able to personalize a treatment plan to meet the specific needs of each patient.

Diagnosing and screening for GI cancers

In the fall of 2011 Swedish opened a new endoscopy center, making it possible to offer a comprehensive menu of GI services to address every facet of GI cancer within the Swedish network.

“From screening and surveillance to the most advanced tertiary and quaternary minimally invasive, non-operative and interventional services, the Swedish Endoscopy Center is an integral part of the collaborative assault on GI cancers,” says Jack Brandabur, M.D., medical director, Swedish Endoscopy.

In this efficient, safe and comfortable environment, highly trained specialists have access to state-of-the art technology, including endoscopic ultrasound (EUS), three-dimensional imaging and high-resolution endoscopy, as well as

capsule endoscopy, deep enteroscopy and the SpyGlass® Direct Visualization System for endoscopic retrograde cholangiopancreatography (ERCP).

Recognizing the fusion of endoscopic technologies, the center features a state-of-the-art unit with both EUS and the newest generation of 3-D fluoroscopy – a first for an endoscopy unit on the West Coast. This

commitment to providing the most advanced imaging technology means that this high-tech hybrid unit can meet the needs of gastroenterologists, surgeons and interventional radiologists.

The center’s gastroenterologists, as well as Swedish thoracic surgeons, have extensive training and expertise in endoscopic treatments for early cancers and precancerous lesions. This allows nonsurgical treatment of some types of tumors. For example, endomucosal resection (EMR) or techniques such as radiofrequency ablation and cryotherapy may help prevent esophageal cancer in patients with precancerous Barrett’s esophagus, as well as help them avoid major surgery, such as esophagectomy.

The new tools that are now available at the Swedish Endoscopy Center are also helping identify pancreatic cancer at an earlier stage, giving more people better treatment options. Using the center’s endoscopic

ultrasound, gastroenterologists are able to locate and sample tumors that are not visible on a CT scan. Patients diagnosed with Stage I or II pancreatic cancer may be good candidates for surgical resection and possible cure.

“We are able to manage the diagnosis and treatment of many GI cancers, and to screen for and treat pre-cancerous conditions, which often reduces the need for surgery,” says Drew Schembre, M.D., medical director, Swedish Gastroenterology. “When traditional surgery becomes the

The Swedish Endoscopy Center’s team of experts includes both physicians and specially trained nurses. Left to right: Drew Schembre, M.D.; Laci Hickman, R.N.; Angie Budinich, R.N.; Donna Madeira, R.N., BSN, CGRN; and Jack Brandabur, M.D.

Thoracic surgeons, surgical oncologists and liver surgeons are integrated members of the GI cancer team at the SCI. Whether surgery becomes part of a patient’s treatment plan, as well as the type of surgery, is part of the GI Tumor Board’s collaborative evaluation. What is unique about the SCI program is the wealth of surgical options and the in-house expertise.

“Not every cancer gets the same surgical procedure,” says thoracic surgeon Brian Louie, M.D. “For example, we evaluate and are able to offer esophageal cancer patients specific procedures, from endoscopic resection and ablation, or minimally invasive vagal sparing esophagectomy for early cancers, to open or robotic surgery for more advanced cancers.”

The SCI is constantly looking to the next generation of technology to enhance the surgical care of GI cancer patients. The SPY Imaging System from Novadaq® Technologies will be the next advanced technology added to the Swedish operating suite. Surgeons performing gastric pull-up surgery to create a new esophagus will be able to use SPY to identify the area of the stomach tube that has the best blood supply, thus reducing complications and ensuring the health of the gastric pull-up.

preferred treatment option, the expertise and technology available through our new endoscopy center gives our surgeon colleagues the best possible roadmap.”

A broad array of treatment options

The value of a program such as the SCI’s GI Cancer Program is the comprehensive menu of treatment options available to each GI cancer patient. In evaluating a particular case, the SCI’s GI cancer specialists are able to consider commercial drugs; endoscopic procedures; conventional, minimally invasive or robotic surgical procedures; and multiple radiation therapies either alone or in combination. An added benefit of receiving care at the SCI is access to appropriate investigational therapies that may not be available anywhere else in the Pacific Northwest – and sometimes the world. Every GI cancer patient can receive complete personalized care from screening to diagnosis and treatment without leaving Swedish.

(Continued)

Left to right: Brian Louie, M.D.; Michael Hart, M.D.; Amir Bastawrous, M.D., MBA

7

Surgical judgment and technical expertise are critical to successful GI surgery of any type. Swedish is one of the few medical centers in the region that has both the expertise and long-term experience to select appropriate candidates for surgery and to surgically manage those patients with the most appropriate techniques and technology.

“Because we are able to carefully select patients who will benefit from surgery, pancreatic cancer surgery is a lot safer than many people might think,” says Michael Hart, M.D., a surgeon with Swedish Surgical Specialists at First Hill. “Morbidity from pancreatic surgery has dropped dramatically. We are now able to successfully resect patients we would not have been able to operate on previously due to age or cardiac morbidity.”

For instance, the Whipple procedure, also called a pancreaticoduodenectomy, is one of the more complex procedures performed at Swedish for Stage I and II pancreatic cancer. During this procedure, surgeons remove the gallbladder, common bile duct, part of the duodenum and the head of the pancreas. Even some patients receiving total pancreatectomies at Swedish are experiencing high success rates.

“Surgeons at Swedish primarily approach colon surgery from a minimally invasive perspective, using laparoscopic or robotic technologies,” says Amir Bastawrous, M.D., MBA, medical director of the Swedish Colon & Rectal Clinic at Swedish/Issaquah and Swedish/First Hill. “We focus on preserving function and reducing recovery time and pain, while obtaining optimal results.”

Swedish, which has seven da Vinci Robotic Surgical Systems®, was among the first medical centers in Seattle to use robotic surgery for colon cancer. Robotic surgery improves visualization and gives the surgeon complete control of multiple instruments, making it possible to reach further and be more successful – resulting in a much lower conversion rate to open surgery

than with laparoscopic surgery. Based on surgical volumes, Swedish surgeons clearly have the most experience with robotic colorectal surgery. The da Vinci system has proven to be particularly useful for rectal surgery, including removing Stage II and III primary cancers.

For about a year, Swedish surgeons have used transanal endoscopic microsurgery (TEM) for rectum cancer. This procedure is an enhancement to one that has been in use in Germany for about 20 years, but had a low adoption rate in the United States due to the expense associated with the required equipment. The new single-incision, rectum-preserving

laparoscopic surgery being used at Swedish utilizes existing laparoscopic instruments. TEM is particularly beneficial for patients diagnosed with Stage T1 rectum cancer who have co-morbidities, as well as those diagnosed with large polyps that could not be removed during a colonoscopy.

Advancements in radiation therapy

The Centers for Advanced Targeted Radiation Therapy at Swedish offers an abundance of radiation therapy options, which allows physicians to select the most appropriate and most convenient therapy for GI cancer patients. The radiation oncology team has built on a tradition of excellence and innovation in radiotherapy at Swedish that is more than 75 years old. Using image-guided

radiation therapy (IGRT), volumetric-modulated arc therapy (VMAT) or stereotactic radiosurgery, Swedish radiation oncologists are able to use the lowest possible dose of radiation to help protect surrounding tissues while destroying cancerous cells.

“The goal at the SCI is to develop and implement radiotherapy technologies that cure more patients and/or reduce the side effects patients experience while undergoing treatment,” says radiation oncologist Vivek Mehta, M.D., medical director of the Centers for Advanced Targeted Radiation Therapy.

(Continued)

Vivek Mehta, M.D.

Chemoradiotherapy has been shown to be the definitive treatment for patients with anal cancer. Historically the radiation treatment fields included the anal canal and at-risk lymph nodes/lymphatic channels. Radiotherapy techniques that have been used for several decades expose a large portion of the bowel and other normal tissues to significant doses of radiation, which place patients at risk for acute side effects, many of which are so severe treatment must be interrupted. In prospective studies during the last several years, IMRT has demonstrated several advantages over conventional treatment. The most important advantage is the reduced doses of radiation to normal organs and structures in the pelvis. VMAT, an improved IMRT technique that was pioneered at the SCI, builds on this knowledge and promises even better patient experiences.

The most recent addition to the Swedish radiation therapy armament is TheraSphere®, a type of radioembolization or selective internal radiation therapy (SIRT) that is used to treat inoperable liver cancer to downstage the cancer so the patient becomes eligible for surgery or to treat the cancer while the patient awaits a liver transplant. Since its introduction at Swedish in 2011, TheraSphere has been the treatment of choice in more than 18 liver cancer cases, providing an alternative to other treatments that require hospitalization and may produce side effects that are detrimental to the patient’s quality of life. TheraSphere is an extremely targeted radiation therapy. Through a small incision in the patient’s leg, the interventional radiologist threads a catheter into the femoral artery and the hepatic artery that feeds the tumor in order to infuse radioactive beads into the blood that feeds the cancerous cells. Although the outpatient procedure is performed in a hospital setting, the patient is conscious and able to return home afterwards.

Cancer-fighting medications and treatment protocols

Medical oncologists at the SCI have a vast armament of medications and treatment protocols to fight GI cancers, including commercially available biologic therapies and chemotherapy, and investigational drugs. In fulfilling its goal of making cancer care available closer to patients’ homes or places of work, the SCI has expanded access to some of these services by offering chemotherapy and infusion therapy services at the new Swedish/Issaquah campus, which opened in July 2011 (see page 17), as well as at clinics at Swedish/Ballard, Bellevue and Swedish/First Hill. Additionally, the new SCI facility at Swedish/Edmonds, which is scheduled to open in spring 2012, will feature a chemotherapy and infusion therapy suite (see page 14). These new facilities feature the ultimate in patient-focused design that emphasizes convenience, comfort and privacy.

The SCI has taken an active role in multiple national and international clinical trials testing the efficacy of new drugs, and has participated in the clinical trials leading to the approval of many of the new drugs developed in the last ten years for colorectal cancer. It was also the site of the first human dose of a new antibody for liver cancer and will continue to be at the forefront of that research as it becomes the first site to begin the Phase II drug testing.

Initiating a new thoracic surgery registry, which has great potential as a resource for esophageal cancer research, is another way the SCI is a leader. Collecting and sharing this type of data among physician-investigators can be a catalyst to new treatments and standards of care.

The SCI has been a member of the Southwest Oncology Group (SWOG), one of the largest National Cancer Institute-supported clinical trials cooperative groups, since the 1970s. Through SWOG, the SCI has access to some of the latest clinical trials and is able to collaborate closely with other cancer centers in initiating or participating in research that will help prevent, detect and treat cancer.

In 2008 the SCI joined similar institutes at seven other highly regarded medical centers to form the Academic GI Cancer Consortium (AGICC), which is dedicated to studying new GI cancer drugs as they come along. This research is particularly beneficial for patients who may have exhausted more conventional drug treatment options.

During the last decade, the SCI has significantly increased its clinical research, participating in numerous federally funded, industry-sponsored and SCI physician-investigator-initiated trials relevant to gastrointestinal cancer. SCI’s GI cancer team is committed to pursuing every possible avenue to identify new medications, surgical and endoscopic therapies, advancements in radiation therapy dosing or delivery, and new guidelines for standards of care and survivorship that will benefit GI cancer patients.

Depth and breadth of services matters

Expertise, experience and an extensive menu of screening, diagnostic and treatment options are the hallmark of a premier cancer program. With the SCI Gastrointestinal Cancer Program, providing access to those resources under one roof and in a cohesive way is making a difference in the lives of patients.

8

Anne M. Larson, M.D., director of The Swedish Liver Center; and Marquis Hart,

M.D., director of transplant surgery.

For liver cancer patients, the Swedish Liver Center offers a multidisciplinary approach via the Swedish Liver Tumor Board. These specialists, who have a special interest and expertise in liver cancer, provide timely and complete care to patients with liver tumors and cancer. Because of the broad scope of treatments available at the center, the board is able to consider multiple options when developing a personalized treatment plan for a specific liver cancer patient. These options include:

• Open and laparoscopic liver resection • Chemoembolization• Radioembolization • Systemic chemotherapy• Immunological therapies • CyberKnife® radiosurgery• Radiofrequency and microwave ablation • Liver transplantation

“We are excited that we can offer a liver cancer patient the full range of available options for the treatment of their liver cancer, including research protocols and integrative care,” says Dr. Larson.

Liver transplantation: Swedish is one of only two adult liver transplant centers serving the four-state organ-procurement region that includes Washington, Alaska, Montana and Idaho. While some liver conditions and complications can be treated with medications, liver transplantation may be the only option for irreversible acute and chronic liver disease or liver cancer.

New Liver Center Broadens Approach to Liver Cancer

The August 2011 arrival of Anne M. Larson, M.D., and her appointment as director of The Liver Center at Swedish, is testament to the commitment Swedish has made to expanding access to care for patients with liver disease. In her new role, Dr. Larson oversees The Swedish Liver Center, a program that promotes customized treatment plans that may include liver disease management, medical and surgical options, the use of state-of-the-art technologies, and liver transplantation.

Gastrointestinal Cancer by the Numbers

The American Cancer Society (ACI) estimated that by the end of 2011, there would be 277,570 new gastrointestinal cancers diagnosed in the United States. Although year-end totals are not yet available, the ACI’s estimate suggests colon and rectal cancers will account for more than half of those new cases (141,210), with about equal frequency in men and women. The ACI also expects men and women will be equally represented in the estimated 44,030 new cases of pancreatic cancer cases. Whereas men will account for almost four times more new esophageal cancer cases than women, women will be diagnosed with liver cancer about three times more often than men1.

Colorectal Cancer

Due to the increased focus on screening and the ability to remove pre-cancerous polyps before they become cancer, mortality in colon and rectum cancer has declined dramatically during the past two decades from 66.3 cases per 100,000 in 1985 to 45.3 cases per 100,000 in 2007. Despite these impressive numbers, however, nearly half of all eligible adults do not get screened. In adults younger than 50, where screening is not recommended, the mortality rate has increased 1.6 percent per year since 19982.

Esophageal Cancer

Although the total number of esophageal cancer cases remains relatively small (about 1 percent of all cancers), the 475 percent increase in new adenocarcinoma cases between 1975 and 2001 (increasing from 4 cases per million to 23 cases per million) makes esophageal cancer the fastest-rising cancer in North America. In the 1970s, squamous cell carcinoma was the most common type of esophageal cancer, with adenocarcinoma relatively rare. During the last three decades that ratio has shifted. Now adenocarcinoma is significantly more common3.

Liver Cancer

For 2011 the American Cancer Institute estimated 26,190 newly diagnosed cases of liver and intrahepatic bile duct cancers in men and women in the United States, with more than 80 percent of those cases hepatocellular carcinoma. Since 1992, the incidence of liver cancer has increased 3.4 percent in men and 3.0 percent in women4.

Pancreatic Cancer

As with most cancers, discovering pancreatic cancer early gives patients the best chance of survival. Nevertheless, the one-year survival rate (all stages) of 26 percent and five-year survival rate (all stages) of just 6 percent5

suggests pancreatic cancer is both difficult to diagnose and difficult to cure.

1 American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011. p.4.; 2 American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011. p.12.; 3 Hoffman, Matthew. Esophageal Cancer on the Rise, www.webmd.com/cancer/features/esophageal-cancer-rise; 4 American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011. p.14.; 5 American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011. p.19.

10

BrainCTSU E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

RTOG 0834 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial

RTOG 0837 Randomized, Phase Il, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide plus Placebo in Patients with Newly Diagnosed Glioblastoma

Breast97517 I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2)

SWOG 0221 Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer

041-00 A Two-Part, Adaptive, Randomized Trial of Ridaforolimus (MK8669) in Com-bination with Dalotuzumab (MK0646) Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Mono-therapy in Estrogen Receptor Positive Breast Cancer Patients

SWOG 0500 A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment

SWOG 0800 A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week

Doxorubicin (A) and Cyclphosphamide (C) Plus Pegfilgrastim (Peg-G) as Neoadju

ACOSOG Z1041 A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel plus Trastuzumab Followed by FEC-75 plus Trastuzumab in Patients with HER2-Positive Operable Breast Cancer

CRC 09096 Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients with Newly Diagnosed Breast Cancer

CTSU ACOSOG Z1071 A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis

CTSU B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemo-therapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2

CTSU C40601 Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

CTSU C40603 Randomized Phase II 2 X 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

CTSU E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

CTSU E3108 A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen

Swedish Cancer Institute Open Research Studies

11

(Continued)

Clinical Trials at the Swedish Cancer InstituteThe Swedish Cancer Institute (SCI) is one of the leading clinical trial sites in the western United States. With more than 100 available studies at any given time involving most types of cancer, a clinical trial could be one part of a personalized treatment plan for many SCI patients.

“Being able to offer a clinical trial to one of my patients is one of the great benefits of working at the SCI,” says Philip Gold, M.D., director of clinical research at the SCI. “It is important for us to have as many tools as possible so we can customize treatment plans and produce the best possible results for each of our patients. A clinical trial, which allows me to use a new medication before it is widely available, may give my patient an advantage in our fight against cancer.”

SCI physician investigators and research partners are at the leading edge of the clinical trials stage of the research process. The SCI is often the only site in the Pacific Northwest – and sometimes the first in the world – to participate in many clinical trials. At the SCI, studies:

• Find new treatments and/or more effective combinations of treatments

• Identify new methods of detecting cancer in its earliest stages

• Discover new ways to improve the quality of life of cancer patients

• Test new approaches to preventing cancer

Making clinical trials available to our patients is a privilege. The SCI is proud to be part of a research process that may result in new medications, devices and treatments being available to cancer patients across the country and around the world.

12

CTSU MA.32 A Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

CTSU N0733 Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2-Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane

LPT112515 A Randomized, Phase III, Open-Label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-Line Trastuzumab plus Chemotherapy in Subjects with HER2-Positive Metastatic Breast Cancer

MR 2011-03 Breast Test for Breast Cancer Using the Remote Diagnosis System (RDS)

RAD001 W2301 A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-Expressing Locally Advanced or Metastatic Breast Cancer

Ca Control

SWOG 0702 A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metas-tases Starting Zoledronic Acid Treatment

Gastroenterology

8059 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane®) in the Treat-ment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

SWOG 0518 Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

SWOG 0713 A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-operative Therapy of Rectal Cancer

SWOG 0809 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy

Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)

SWOG 0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

SWOG 1005 A Phase II Study of MK-2206 (NSC-749607) as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer

ARQ 97-A-U252 A Randomized, Placebo-Controlled, Phase ½ Study of ARQ 197 in Combination with Irinotecan and Cetuximab in Subjects with Metastatic Colorectal Cancer with Wild-Type KRAS who Have Received Front-Line Systemic Therapy

B-500 HALO Patient Registry: Ablation of Barrett’s Esophagus

CA046 A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Meta-static Adenocarcinoma of the Pancreas

CAUY922AUS06T Phase Ib with Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer

CTSU C80405 A Phase III Trial of Irinotecan/ 5-FU/Leucovorin or Oxaliplatin/5-FU/Leu-covorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Beva-cizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

CTSU C80702 A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

CTSU E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion

D9010C00008 A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP inhibitor, olaparib, Alone in Previously-Treated Patients with Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status

D9010C00009 A Dose Finding and Phase II Study of AZD6244 (Hyd-Sulfate) in Combination with Irinotecan in Second-Line Patients with K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer

Perifosine 343 A Phase III Randomized Double-Blind Study to Assess the Efficacy and Safety of Perifosine plus Capecitabine versus Placebo plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer

Genitourinary

SWOG 0925 A Randomized Phase II Study of Combined Androgen Deprivation versus Combined Androgen Deprivation with IMC-A12 for Patients with New Hormone-Sensitive Metastatic Prostate Cancer

SWOG 0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

SWOG 1014 Abiraterone Acetate Treat-ment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II

CTSU C90202 A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone

CTSU C90601 A Randomized Doubled-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma

Gynecologic

004-00 A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer

Head and Neck

CTSU E1305 A Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck Cancer

CRC 0605 Prospective, Longitudinal, Multicenter, Descriptive Registry of Patients Receiving Therapy other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma

Leukemia

SWOG 0535 A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozo-gamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia

SWOG 0703 A Phase II Trial of Azacitidine plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia

SWOG 0805 Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chro-mosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL)

SWOG 0910 A Phase II Study of Epratu-zumab in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Precursor B-cell Acute Lymphoblastic Leukemia

SWOG 0919 A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leuke-mia (AML)

SWOG 9007 Cytogenetic Studies in Leukemia Patients

SWOG 9910 Leukemia Centralized Refer-ence Laboratories and Tissue Repositories

SWOG C10403 An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)

CA180-330 Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

CC-5013-CLL-002 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy

CC-5013-CLL-008 A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) versus Chloram-bucil as First-Line Therapy for Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia

CTSU E2905 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (CC-5013) Alone and in Combination with Darbepoietin-Alpha (DA) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia

Bosutinib IND Single Patient IND for the Compassionate Use of Bosutinib for Chronic Myeloid Leukemia

011 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy

Lung

109493 A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer

SWOG 0709 A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics

SWOG 0720 Phase II ERCC 1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

SWOG 0802 A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)

SWOG 0819 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab

with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

SWOG 0905 A Phase I/Randomized Phase II Study of Cediranib (NSC #732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma

2007-LC3 A Breath Test for Lung Cancer

ACOSOG Z4099 A Randomized Phase III Study of Sublobar Resection (+/- Brachy-therapy) versus Stereotactic Body Radiation Therapy in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

ARQ197-A-U302 A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non–Small Cell Lung Cancer (NSCLC)

CP14B012 A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

CTSU C140503 A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer

CTSU C30801 A Randomized Phase III Double-Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer

CTSU E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

OSI-906-207 A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination with OSI-906 or Placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

20090321 (EFC11553) Randomized Phase III Trial of Gemcitabine/Carboplatin with or without BSI-201 (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Un-

treated Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Lung, Breast or Prostate

MR 2010-18 Point of Care of High-Throughput Biological Breath Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) After Radiologic and Nuclear Events

Lymphoma

SWOG 0806 A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)

SWOG 0816 A Phase II Trial of Response- Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Interim FDG-PET Imaging

B1931008 An Open-Label, Randomized, Phase III Study of Inotuzumab Ozogamicin Administered in Combination with Rituximab Compared to Defined Investigator’s Choice Therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma who Are Not Candidates for Intensive High-Dose Chemotherapy

C18083/3064/NL/MN An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

CTSU C50303 A Phase III Randomized Study of R-CHOP versus Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

CTSU C50604 Phase II Trial of Response- Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin’s Lymphoma

Melanoma

SWOG 0933 Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma

CTSU E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Myeloma

SWOG 0833 Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients with Multiple Myeloma (MM): A Phase II SWOG Trial for Patients <= 65 Years

CLBH589B2207 A Phase Ib, Multicenter, Open-Label, Dose-Escalation Study of Oral LBH589 and IV Bortezomib in Adult Patients with Multiple Myeloma

CLBH589D2308 A Multicenter, Random-ized, Double-Blind, Placebo-Controlled Phase III Study of Panobinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma

Not Site Specific

CRC 0644 Adaptive Radiotherapy Utilizing Information Obtained from Volume View Conebeam Images Obtained During Image-Guided Radiotherapy Treatment

CRC 08061 Comparison of Volumetric-Modulated Arc Therapy (VMAT) to Image-Modulated Radiation Therapy (IMRT): A Pilot Study in a Standard of Care Setting

UW PK Pharmacokinetics of Under-Studied Drugs Used During Pregnancy

SWOG 0711 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction

13

Swedish/Edmonds Expanding to Improve Access to Cancer Services

As 2011 came to a close, leadership from Swedish/Edmonds, and the Swedish Cancer Institute (SCI) and its affiliate Puget Sound Cancer Centers (PSCC) were eagerly awaiting final approvals and the ground breaking for a new two-story, 16,000-square-foot building on the Swedish/Edmonds campus. Together, this new medical oncology facility and the adjacent existing radiation therapy center will provide comprehensive cancer-care services for residents of Edmonds and communities in North King and South Snohomish counties.

This project will help meet one of the cornerstone goals of the SCI-PSCC affiliation, which occurred in July 2010: increase access to subspecialty cancer care for residents living north of Seattle and to the new medications and treatment modalities that are currently available only through clinical trials.

“All of us at PSCC, including our doctors, nurses, and clinical and administrative staff, are excited to build and expand access to state-of-the-art oncology care and research in the local community,” says Richard McGee, M.D., FACP, president of Puget Sound Cancer Centers. “Affiliation with SCI has made this possible despite the very difficult financial and resource-restricted environment in which the health-care industry is operating today. We are convinced that together we can expand opportunities for our cancer patients, which otherwise we would not be able to accomplish.”

The new building, which is on schedule to open in spring 2012, will feature a medical oncology suite with physician services provided by PSCC, and chemotherapy and infusion services. All patient-care areas have been designed to provide the ultimate in patient privacy, comfort and safety.

Plans are also under way to redesign the adjacent existing SCI Edmonds Cancer Center to expand and enhance services. The first floor will be renovated to house a new linear accelerator that will complement the comprehensive menu of advanced targeted radiation therapies currently available throughout the SCI network. The second floor will become a resource center with space for patient and family education, social services and meeting rooms for support groups and classes, and will also house office space for specialists and integrated care providers.

In 2010, more than 2,600 cancer patients received care from the SCI, PSCC and other local cancer-care providers affiliated with Swedish/Edmonds. SCI appreciates that if given the choice, patients prefer to receive care close to where they live and/or work, while still having easy access to the SCI network that offers unique expertise and technology should they need it. The nearly $15-million construction project, future renovations and technology upgrades at Swedish/Edmonds are tangible responses to that awareness – placing patients squarely in the center of SCI strategic planning and targeted growth of its network.

The new 16,000-square-foot, two-story building at Swedish/Edmonds will help the SCI and its affiliate Puget Sound Cancer Centers increase access to subspecialty cancer care for patients living north of Seattle. The architects have designed a healing environment that draws on the serenity of nature and natural lighting for inspiration. Renderings courtesy of Perkins+Will.

14

17

SCI at Issaquah Now Serving the Eastside

In July 2011 the Swedish Cancer Institute (SCI) opened a new facility at the Swedish/Issaquah campus – the first opportunity for the SCI to integrate its medical oncology, infusion therapy and radiation oncology services into one Swedish clinic site.

“Our ability to duplicate cancer services that used to be available only in Seattle, underscores our desire to make cancer treatment more convenient for patients who live on the Eastside,” says Ken Kraemer, M.D., a medical oncologist at Swedish/Issaquah.

Addressing mind, body and spiritThe new cancer center at Issaquah embodies the spirit of the SCI and its dedication to treating cancer, while caring for patients. As is true throughout the SCI cancer-care network, the cancer team at Issaquah delivers personalized care and helps patients think beyond treatment to survival.

“In designing our new facility and the services we would provide, our goal was to meet as many of our patients’ personal needs as possible – not only through our medical expertise, but also through educational and family support services,” says medical oncologist Tanya Wahl, M.D. “We are proud of the patient-focused environment we created, which speaks to the important role comfort and compassion play in our approach to developing a comprehensive cancer treatment program.”

Cancer services at Issaquah include:• Medical Oncology• Infusion Therapy• Radiation Therapy• Surgical Oncology (breast, thoracic and colon/rectal clinics)• Integrated Care (naturopathic medicine, oncology social work, hereditary

cancer/genetic counseling, music and massage therapy programs, health education and nutritional counseling)

• Cancer related retail products• Access to clinical research

“Providing access to cancer services at Issaquah means we are able to provide our patients the best level of care and also develop a strong clinical research program on the Eastside,” says medical oncologist Kasra Karamlou, M.D.

Advanced radiation technology and techniquesRadiation oncologists with years of experience and broad expertise are part of the multidisciplinary cancer team now available at Swedish/Issaquah.

“The radiation oncology and medical oncology departments are fully integrated, allowing seamless care among providers,” says Jim Spiegel, M.D., medical director of radiation oncology at Swedish/Issaquah.

The SCI at Issaquah radiation oncology department is able to offer a multitude of technical advancements for radiation therapy, including the newest generation of linear accelerator with complete image-guided radiotherapy capability (the Elekta Infinity) and also Active Breathing CoordinatorTM (ABC), which provides patients with left-sided breast cancer maximum protection from radiation to their hearts. This noninvasive, advanced technology administers radiation during a deep-breath hold, which increases the physical distance between the target (breast tissue or chest wall) and the heart, thereby minimizing incidental radiation to the heart and reducing the risk of radiation-induced heart disease.

For more information about cancer services at the SCI at Issaquah, please call 425-313-4200.

The cancer experts at the newly opened SCI Cancer Center at Swedish/Issaquah provide highly sophisticated treatments and procedures in a tranquil, soothing setting. Every area of the center has been designed to make the patient as comfortable as possible – including the lobby (top), radiation therapy (lower left), and the multi-bay infusion therapy unit (lower right). Photos courtesy of Perkins+Will.

18

Donations Expand the Reach of SCI’s Cancer-Fighting Team

Through the Swedish Medical Center Foundation many individuals, families, corporations and foundations support the Swedish Cancer Institute (SCI) in its efforts to fight cancer. Since the beginning of the Campaign for Swedish in 2007, more than 16,200 gifts have provided over $17 million to advance research, provide patient assistance, promote programs, equip clinics and build new facilities at SCI.

Supporting research Although funding cancer research may seem less tangible than building a new clinic or procuring the latest cancer-fighting technologies, few contributions can match research support for its impact on the lives of patients at Swedish and far beyond. Philanthropic partnerships that provide funding for clinical research studies are critical to the SCI’s active search for better treatments and improved outcomes. Donors who provide funds for research studies give the SCI’s physicians expanded opportunities to develop their understanding and to share their knowledge with others who are also engaged in finding new treatments for cancer. These donors are an important part of the SCI team – helping to make it possible for our physicians to give hope to patients in the form of access to investigational therapies that may make a difference in their ability to survive cancer.

Supporting patients Many individuals and organizations who donate to the SCI are motivated by a passionate desire to support cancer patients in their time of need, recognizing that the fight against cancer is often more than just a medical challenge. Thanks to their generosity, the SCI Patient Assistance program is able to provide non-medical financial support to patients who face a variety of issues that might keep them from getting the treatments they need. This program, which is funded by philanthropy, offers emergency assistance for rent and utility bills, transportation, child care, insurance and other essentials to ensure that patients are not forced to choose between meeting daily expenses and getting the cancer treatments prescribed for them.

Donations to the Foundation also make it possible for the SCI to offer integrative care programs, including art and music therapy, at no cost to patients, and their families and caregivers. These therapies are healing modalities that are intended to integrate emotional, physical and spiritual care by facilitating creative ways for patients to respond to their cancer experience and providing an outlet for feelings and emotions that may be difficult to put into words.

Supporting care close to home The generosity of Swedish donors also has supported the expansion of the SCI cancer-care network at Swedish/Issaquah and Swedish/Edmonds. For example, philanthropy has funded a position for a social worker to provide support services for cancer patients and their families at Swedish/Issaquah, and a gala held at the end of 2011 raised funds for the expansion and renovation projects at Swedish/Edmonds.

Swedish Medical Center Foundation and the SCI are honored by the dedication and commitment of all donors who give their financial support to help the SCI advance the fight against cancer.

19

2010 Cancer Sites TOTAL CASES

TOTAL PERCENT

ANALYTIC CASES

NONANALYTIC CASES

BREAST

1224 21.30% 970 254

ENDOCRINE

Thyroid 168 3.00% 136 32

Other Endocrine Glands 136 2.70% 84 52

GASTROINTESTINAL

Stomach 57 1.00% 38 19

Small Intestine 19 0.30% 14 5

Colon 185 3.20% 122 63

Rectum/Rectosigmoid 122 2.10% 90 32

Anus, Anal Canal, Anorectum 22 0.40% 17 5

Liver 62 1.10% 45 17

Gallbladder 3 0.10% 1 2

Bile Ducts 13 0.20% 12 1

Pancreas 105 1.80% 86 19

Other Digestive 5 0.10% 5 0

GENITOURINARY

Prostate 718 12.60% 529 189

Testis 28 0.50% 15 13

Kidney/Renal Pelvis 124 2.20% 97 27

Ureter 3 0.00% 2 1

Bladder 106 1.90% 78 28

Penis 5 0.10% 4 1

Other Urinary Organs 2 0.00% 2 0

GYNECOLOGIC

Vulva 24 0.50% 20 4

Vagina 1 0.00% 0 1

AdenoCA Cervix Insitu 45 0.80% 28 17

Cervix 59 1.10% 51 8

Uterus 250 4.50% 235 15

Ovary 143 2.70% 117 26

Other 17 0.30% 15 2

2010 Cancer Sites TOTAL CASES

TOTAL PERCENT

ANALYTIC CASES

NONANALYTIC CASES

HEAD AND NECK

Lip and Oral Cavity 73 1.20% 60 13

Tonsil 22 0.40% 20 2

Pharynx 22 0.30% 16 6

Nasal Cavity/Sinuses/Middle Ear 5 0.10% 4 1

Major Salivary Glands 16 0.30% 12 4

Larynx 30 0.50% 23 7

HEMATOLOGY

Hematopoietic/Reticuloendothelial 280 5.50% 92 188

Hodgkin’s Disease 31 0.50% 18 13

Non-Hodgkin’s Lymphoma 168 3.10% 105 63

MUSCULOSKELETAL

Bones/Joints/Cartilage 16 0.30% 7 9

Connective and Soft Tissue 40 0.70% 25 15

Retroperitoneum 7 0.10% 5 2

Peritoneum, Omentum, Mesentery 6 0.10% 6 0

NEURO/ CENTRAL NERVOUS SYSTEM

Brain 269 4.70% 183 86

Other Central Nervous System 172 3.20% 110 62

SKIN

Melanoma 84 1.60% 45 39

Non-Melanoma 12 0.30% 6 6

THORACIC

Esophagus 58 1.10% 46 12

Bronchus and Lung 544 9.60% 417 127

Heart/Mediastinum/Pleura 29 0.40% 20 9

OTHER

Eye and Adnexa 15 0.30% 13 2

Kaposis Sarcoma 5 0.10% 3 2

Unknown or Other Ill-Defined Site 60 1.10% 46 14

TOTAL 5610 100% 4095 1515

Swedish Cancer Registry 2010 — Analytic Cancer Site Listing

Analytic cancer cases are those having been diagnosed and/or having their first course of treatment at a Swedish facility. Nonanalytic cases are those patients seen and/or treated for subsequent treatment.

20

Drescher C, Hawley S, Thorpe JD, Marticke S, McIntosh M, Gambhir S, Urban N. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. NCI Translational Science Meeting. July 28, 2011, Washington DC.

Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett DR, Foltz G, Lin B. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics Jan 2011; 12:11.

Fang X, Yoon JG, Li L, Tsai Y, Zheng S, Hood L, Goodlett D, Foltz G & Lin B. Landscape of the SOX2 protein–protein interactome. Proteomics Jan 2011;11:921-934.

Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with meta-static esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415). Journal of Thoracic Oncology. 5(9):1472-1476, September 2010.

Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad S, El-Khoueiry A, Messino M, Holcombe R, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangio-carcinoma: Southwest Oncology Group study S0202 Cancer Chemotherapy and Pharma-cology, 2011 May 10.

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohtomo T, Philip PA. A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 29: 2011 (suppl; abstr 4085) Poster Presentation.

Bohanes PO, Goldman B H, Leichman LP, Blanke CD, Iqbal S, Thomas CR, Corless CL, Billingsley KG, Danenberg KD, Zhang W, Benedetti JK, Gold PJ, Lenz H. Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) pa-tients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative

group study (SWOG S0356). J Clin Oncol 29: 2011 (suppl; abstr 4023) Poster Discussion.

McKay JD, Truong T, Gaborieau V, Chabrier A, Chuang SC, Byrnes G, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Holcatova I, Janout V, Foretova L, Lagiou P, Trichopoulos D, Benhamou S, Bouchardy C, Ahrens W, Merletti F, Richiardi L, Talamini R, Barzan L, Kjaerheim K, Macfarlane GJ, Macfarlane TV, Simonato L, Canova C, Agudo A, Castellsagué X, Lowry R, Conway DI, McKinney PA, Healy CM, Toner ME, Znaor A, Curado MP, Koifman S, Menezes A, Wünsch-Filho V, Neto JE, Garrote LF, Boccia S, Cadoni G, Arzani D, Olshan AF, Weissler MC, Funkhouser WK, Luo J, Lubiński J, Trubicka J, Lener M, Oszutowska D, Schwartz SM, Chen C, Fish S, Doody DR, Muscat JE, Lazarus P, Gallagher CJ, Chang SC, Zhang ZF, Wei Q, Sturgis EM, Wang LE, Franceschi S, Herrero R, Kelsey KT, McClean MD, Marsit CJ, Nelson HH, Romkes M, Buch S, Nukui T, Zhong S, Lacko M, Manni JJ, Peters WH, Hung RJ, McLaughlin J, Vatten L, Njølstad I, Goodman GE, Field JK, Liloglou T, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, González CA, Quirós JR, Martínez C, Navarro C, Ardanaz E, Larrañaga N, Khaw KT, Key T, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Linseisen J, Boeing H, Hallmans G, Overvad K, Tjønneland A, Kumle M, Riboli E, Välk K, Vooder T, Metspalu A, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Blanché H, Gut IG, Galan P, Heath S, Hashibe M, Hayes RB, Boffetta P, Lathrop M, Brennan P. A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet. 2011 Mar;7(3):e1001333. Epub 2011 Mar 17. Erratum in: PLoS Genet. 2011 Apr;7(4). doi: 10.1371/annotation/9952526f-2f1f-47f3-af0f-1a7cf6f0abc1. Voodern, Tõnu [corrected to Vooder, Tõnu].

Sakoda LC, Loomis MM, Doherty JA, Neuhouser ML, Barnett MJ, Thornquist MD,Weiss NS, Goodman GE, Chen C. Chromosome 15q24-25.1 variants, diet, and lung cancer susceptibility in cigarette smokers. Cancer Causes Control. 2011 Mar;22(3):449-61. Epub 2011 Jan 13.

Fong PY, Fesinmeyer MD, White E, Farin FM, Srinouanprachanh S, Afsharinejad Z, Mandelson MT, Brentnall TA, Barnett MJ, Goodman GE, Austin MA. Association of diabetes susceptibility gene calpain-10 with pancreatic cancer among smokers. J Gastrointest Cancer. 2010 Sep;41(3):203-8.

Wang CL, Macdonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD. Positron Emission Mammography: Correlation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status and 18F-FDG. Am J Roentgenol. 2011 Aug;197(2):W247-55.

Henson JW, Wulff, J. Inpatient Management of Neuro-oncology Patients. In Josephson, Freeman and Likosky, Neurohospitalist Medicine, Cambridge University Press, Cambridge, Ch 7, pp 97-115, UK 2011.

Irving GA, Backonja MM, Dunteman E, Vanhove GF, Tobias J, Lu S-P. A. Multicenter, Randomized, Double-Blind, Controlled Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia. Pain Medicine 2010;12(1):99-109.

Irving GA, Backonja, M, Rauck R, Webster LR, Tobias JK, Vanhove GF. NGX-4010, a Capsaicin 8% Dermal Patch, Administered Alone or in Combination With Systemic Neuropathic Pain Medications, Reduces Pain in Patients With Postherpetic Neuralgia Clinical Journal of Pain., 12 July 2011 epub doi: 10.1097/AJP.0b013e318227403d.

Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. Neurosurgery. 2011 May 14.

Lusis EA, Travers S, Jost SC, Perry A. Glioblas-tomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: a clini-copathological study of 3 cases. Neurosurgery. 2010 Sep;67(3):811-7; discussion 817.

Kaplan HG, Malmgren JA, Atwood MA. Myelodysplastic syndrome and acute myeloid leukemia incidence following primary breast cancer treatment. BMC Cancer 2011, 11:260. doi:10.1186/1471-2407-11-260. www.biomedcentral.com/1471-2407/11/260.

Malmgren JA, Atwood MK, Kaplan HG. Mammography-detected breast cancer over time among patients 75 and older at a community-based cancer center: 1990-2008. J Clin Oncol 29; 2011 (suppl; abstr 9086).

Kaplan HG, Malmgren JA, Atwood MK. Positive response to neoadjuvant cyclophos-phamide and doxorubicin in topoisomerase II non-amplified/HER2/neu negative/polysomy 17 absent breast cancer patients. Cancer Management and Research 2010:2 213–218.

Beatty JD. Start by decreasing unnecessary postmastectomy irradiation. Arch Surg. 2010 Sep;145(9):878-9. Schummer M, Beatty JD, Urban N. Breast cancer genomics: normal tissue and cancer markers. Ann N Y Acad Sci. 2010 Oct;1210:78-85.

Beatty JD, Adachi M, Bonham C, Atwood M, Potts MS, Hafterson JL, Aye RW. Utilization of cancer registry data for monitoring quality of care. Am J Surg. 2011 May;201(5):640-4.

Dooley WC, Algan O, Dowlatshahi K, Frances-catti D, Tito E, Beatty JD, Lerner AG, Ballard B, Boolbol SK. Surgical perspectives from a prospective, nonrandomized, multicenter study of breast conserving surgery and adjuvant elec-tronic brachytherapy for the treatment of breast cancer. World J Surg Oncol. 2011 Mar 7;9:30.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, et al. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Meno-pausal Status. Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8.

Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, Gambhir SS. Early Diagnosis of Ovarian Carcinoma: Is a Solution in Sight? Radiology. 2011 May;259(2):329-45.

Strauss R, Li Z, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher CW, Urban N, Bartek J, Lieber A. Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity. PLoS ONE. 2011 Jan 14;6(1):e16186.

Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK, Urban N, Drescher C, Hemminki A, Fender P, Lieber A. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nature Medicine. 2011 Jan;17(1):96-104.

Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O’Briant K, Schummer M, Karlan B, Urban N, Tewari M, Drescher C, Knudsen BS. Activation of the MEK-S6 Pathway in High-grade Ovarian Cancers. Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):499-508.

2011 Annual Report BibliographyThis bibliography features recent publications and presentations by the Swedish Cancer Institute members and affiliated physicians.

Malmgren JA, Atwood MK, Kaplan HG. Increase in mammography detected breast cancer over time among 40-49 year old patients at a com-munity based cancer center: 1990-2008. J Clin Oncol 28:15s, 2010 (suppl; abstr 1605).

Harsha WJ, Kau RL, Kim N, Hayden RE. Effects of antithrombogenic agents on microvenous anastomoses in a rat model. Arch Otolaryngol Head Neck Surg. 2011 Feb;137(2):170-4.

Markell KW, Hunt BM, Charron PD, Kratz RJ, Nelson J, Isler JT, Steele SR, Billingham RP. Prophylaxis and management of wound infec-tions after elective colorectal surgery: a survey of the American Society of Colon and Rectal Surgeons membership. J Gastrointest Surg. 2010 Jul;14(7):1090-8. Epub 2010 May 15.

Buduhan G, Orlina J, Louie B, Vallieres E, Aye R. Endoscopic and manometric position-related characteristics of the normal gastroesophageal junction. Surg Endosc. 2010 Sep;24(9):2165-9. Epub 2010 Feb 21.

Louie BE, Kapur S, Farivar AS, Samuel J. Youssef, Gorden J, Aye RW and Vallières E. Safety and Utility of Mediastinoscopy in Non-Small Cell Lung Cancer in a Complex Mediastinum. Annals of Thoracic Surgery. 2011; 92:278-83.

Mayberg MR. Endoscopic endonasal surgery. J Neurosurg. 2011 Jun; 114(6); 1541-2; discussion 1542-3. Epub 201- Dec 17.

Mayberg MR. Bone flap cultures. J Neurosurg. 2011 Jun;114(6):1744-5; discussion 1745. Epub 2011 Mar 4. Eboli P, Shafa B, Mayberg MR. Intraoperative CT registration and electro-magnetic neuronavigation for transsphenoidal pituitary surgery: accuracy and time-effective-ness. J. Neurosurgery. 2011 Feb;114(2):329-35.

Mehta VK, Algan O, Griem KL, Dickler A, Haile K, Wazer DE, Stevens RE, Chadha M, Kurtzman S, Modin SD, Dowlatshahi K, Elliott KW, Rusch TW. Experience with an electronic brachytherapy technique for intracavitary accelerated partial breast irradiation. Am J Clin Oncol. 2010 Aug;33(4):327-35.

Mehta VM and Wong TP “KV CBCT-guided intensity-modulated radiotherapy using the Elekta Synergy system in a patient with locally advanced Tonsillar Carcinoma”, Chapter 16G. Image-Guided Radiation Therapy – A Clinical Perspective, edited by A.J. Mundt and J.C. Roeske, People’s Medical Publishing House -USA, page 248-251, 2011.

Fesinmeyer MD, Mehta V, Blough D, Tock L, Ramsey SD. Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):675-81. Epub 2010 Feb 3.

Taras AR, Thorpe JD, Morris AD, Atwood M, Lowe KA, Beatty JD. Irradiation effect after mastectomy on breast cancer recurrence in patients presenting with locally advanced disease. Am J Surg. 2011 May;201(5):603-7.

Paley PJ, Veljovich DS, Shah CA, Everett EN, Bondurant AE, Drescher CW, Peters WA 3rd. Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases. Am J Obstet Gynecol. 2011 Jun;204(6):551.e1-9. Epub 2011 Mar 16.

McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, Goff BA, Gray HJ, Malpass TW. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2011 Aug 15;117(16):3731-40. doi: 10.1002/cncr.25967.

Thrall MM, Paley P, Pizer E, Garcia R, Goff BA. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol. 2011 Aug;122(2):242-5. Epub 2011 Apr 9.

Press JZ, Allison KH, Garcia R, Everett EN, Pizer E, Swensen RE, Tamimi HK, Gray HJ, Peters WA 3rd, Goff BA. FOXP3+ regulatory T-cells are abundant in vulvar Paget’s disease and are associated with recurrence. Gynecol Oncol. 2011 Feb;120(2):296-9.

Newell MS, Birdwell RL, D’orsi CJ, Bassett LW, Mahoney MC, Bailey L, Berg WA, Harvey JA, Herman CR, Kaplan SS, Liberman L, Mendelson EB, Parikh, JR, Rabinovitch R, Rosen EL, Sutherland ML . ACR Appropriateness Criteria on Nonpalpable Mammographic Findings. Journal of the American College of Radiology 2010; 7:920-930.

Naiem A, Keeler E, Bassett LW, Parikh JR, Bastani R, Reuben DB. Cost-effectiveness of Increasing Access to Mammography through Mobile Mammography of Older Women. Journal of the American Geriatric Society 2009; 57(2):285-90.

Ficarra V, Benway BM, Bhayani SB, Rogers CG, Porter JR, Guazzoni G, Buffi N, Mottrie A. Reply from authors re: Ricardo Brandina, Inderbir S. Gill. Robotic partial nephrectomy:

new beginnings. Eur Urol 2010;57:778-9. Eur Urol. 2010 Jul;58(1):53-6.

Rao M, Cao D, Chen F, Ye J, Mehta V, Wong T, Shepard D. (2010) Comparison of anatomy-based, fluence-based and aperture-based treatment planning approaches for VMAT, Phys Med Biol, 55: 6475-6490.

Chen F, Rao M, Ye J, Wu J, Wong T, Saini J, Mehta V, Shepard D, Cao D. (2010) Are 2D detector array sufficient for VMAT QA? Int J Rad Onc Bio Phy, 78(3), S822.

Rao M, Wu J, Cao D, Ye J, Chen F, Wong T, Mehta V, Shepard D. (2010) Investigation of dose calculation accuracy in VMAT planning for SBRT lung treatment. Int J Rad Onc Bio Phy, 78(3), S774.

Rao M, Wu J, Cao D, Ye J, Chen F, Wong T, Mehta V, Shepard D. (2010) Investigation of the interplay effect between field segments and tumor motion during VMAT and IMRT delivery. Med Phys, Vol 37, No. 6, 3339.

Resta R. (2011) Are genetic counselors just misunderstood? Thoughts on the relationship between the genetic counseling profession and the disability community: A commentary. Ameri-can Journal of Medical Genetics 155:1786-7.

Resta R, McCarthy Veach P, Charles S, Vogel K, Blasé T, Palmer CGS (2010) Publishing a master’s thesis: A guide for novice authors. Journal of Genetic Counseling 19:217-227.

Resta R (2010) Complicated shadows: A critique of autonomy in genetic counseling practice. Chapter in Genetic Counseling Advanced Practice Text. Leroy BS, McCarthy Veach P, Bartels DB (eds). New York: John Wiley & Sons. pp. 13-30.

Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adeno-carcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1;28(22):3605-10. Epub 2010 Jul 6.

Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, Rostad S, Foltz G. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One. 2011 Jan 7;6(1):e16146.

Shepard DM, Cao D. Clinical implementation of intensity-modulated arc therapy. Front Radiat Ther Oncol. 2011;43:80-98. Epub 2011 May 20. Review.

Shepard DM, Cao D. Clinical Implementation of Intensity-Modulated Arc Therapy. Advances in the Treatment Planning and Delivery of Radiotherapy, ed 2. Edited by J.L. Meyer. S Karger AG, 2011.

Shepard DM, Cao D, Wu J, Jin JY, Lee C, and Miller D. Non-CT-based IGRT. Imaging in Medical Diagnosis and Therapy. Edited by WR Hendee and X.A. Lee. Taylor and Francis, 2011.

Schild SE, Ramalingam SS, Vallières E. Management of Stage III Non-Small Cell Lung Cancer In: UpToDate, Basow, D (Ed), UpTo-Date, Waltham, MA, 2011.

Park DR, Vallières E, Mason RJ, Broaddus VC, Martin TR, King TE, Schraufnagel DE, Murray JF and Nadel JA. Pneumomediastinum and Mediastinitis. (eds) Murray & Nadel’s Textbook of Respiratory Medicine 5th edition, Elsevier Saunders, Chapter 76: 1836-1858, 2010.

Holmberg LA, Goff B, Veljovich D. Unexpected gastrointestinal toxicity from Docetaxel/Car-boplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2011 May 1;121(2):426. Epub 2011 Feb 15. No abstract available.

Wong TP, Saini J, Chen F, Rao M, Cao D, Ye J, Afghan M, Wu J, Shepard D, Mehta V. (2010) Assessment of PTV margin for image guided stereotactic body radiotherapy for lung cancer, Int J Rad Onc Bio Phy, 78(3), S788.

Shepard D, Cao D, Mehta V, Chen F, Rao M, Wong T. (2010) Initial clinical experience with Monaco VMAT. Med Phys, Vol 37, No. 6, 3219.

Neuss MN, Flamm C, Shulman LN, Tomkins JE, Ward JC. Report on the ASCO 2010 Provider-Payer Initiative Meeting. J Oncol Pract. 2011 May;7(3):136-40.

West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011 Mar 20;29(9):1095-8. Epub 2011 Feb 22.

©2012 SWEDISH HEALTH SERVICES. ALL RIGHTS RESERVED. CI-11-11216 1/12

Arnold Pavilion

1221 Madison St.

Seattle, WA 98104

www.swedish.org/cancer